Source: Eur Respir J 2006; 27: 1168-1174
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Ernst P., Baltzan M., Deschenes J., Suissa S.. Low-dose inhaled and nasal corticosteroid use and the risk of cataracts. Eur Respir J 2006; 27: 1168-1174

Member's Comments

No comment yet.

Related content which might interest you: Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Inhaled corticosteroids and hospitalisation due to exacerbation of COPD Source: Eur Respir J 2003; 22: 286-289 Year: 2003 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 Osteoporosis risk assessment in elderly male patients with COPD who use inhaled corticosteroids Source: Annual Congress 2006 - COPD therapy Year: 2006 Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Source: Eur Respir J 2003; 21: 260-266 Year: 2003 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Children with mild asthma: do they benefit from inhaled corticosteroids? Source: Eur Respir J 2002; 20: 1470-1475 Year: 2002 The role of nebulised budesonide in the treatment of exacerbations of COPD Source: Eur Respir J 2007; 29: 660-667 Year: 2007 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005 Inhaled maintenance therapy and risk of first or subsequent emergency department visit/hospitalization in patients with COPD Source: Annual Congress 2006 - COPD therapy Year: 2006 Oral corticosteroids in the treatment of exacerbation of severe asthma Source: Virtual Congress 2020 – Exhaled biomarkers of asthma and the asthma burden Year: 2020 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002 Audit of inhaled corticosteroid prescription in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2010 - COPD: management Year: 2010 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 COPD: an inhaled corticosteroid-resistant, oral corticosteroid-responsive condition Source: Eur Respir J 2006; 27: 863-865 Year: 2006 An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019 Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Risk of pneumonia and exacerbations of chronic obstructive pulmonary disease(COPD) with inhaled corticosteroid (ICS) use: a Singapore perspective Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 Effects of inhaled corticosteroids on airway inflammations of different types in patients with chronic obstructive pulmonary disease or asthma in stable phase Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009